10-K: BioVie Inc. Files 10-K, Reports on Clinical Programs and Financials

BioVie Inc. released its annual 10-K filing, detailing progress in its clinical programs for neurological disorders and liver disease, along with its financial results for the fiscal year ended June 30, 2024.

Summary

• BioVie Inc. is a clinical-stage company focused on developing therapies for neurological and neurodegenerative disorders and advanced liver disease.
• The company's lead drug candidate, bezisterim (NE3107), is being investigated for Alzheimer's disease (AD), Parkinson's disease (PD), and long COVID.
• A Phase 3 clinical trial of bezisterim for mild to moderate AD showed a signal of efficacy in a per-protocol population, but was underpowered due to significant protocol deviations at some study sites.
• A Phase 2 study of bezisterim for PD met its objectives, showing improvements in motor and non-motor symptoms.
• BioVie received a $13.1 million grant from the U.S. Department of Defense to evaluate bezisterim for neurological symptoms associated with long COVID.
• The company is also developing BIV201 for the treatment of ascites due to chronic liver cirrhosis, with Phase 3 trial designs being finalized after receiving FDA guidance.
• The company reported a net loss of approximately $33.0 million for the year ended June 30, 2024, compared to a net loss of $50.3 million for the previous year.
• Research and development expenses decreased to approximately $23.1 million from $33.3 million in the prior year, primarily due to the completion of clinical studies.
• Selling, general, and administrative expenses decreased to approximately $8.8 million from $11.6 million in the prior year.
• As of June 30, 2024, the company had approximately $23.8 million in cash and cash equivalents and a working capital of approximately $14.7 million.
• The company has an accumulated deficit of approximately $334.2 million and has not generated any revenue to date.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in clinical programs and a decrease in net loss, the underpowered AD trial, lack of revenue, and need for additional capital raise concerns. The ongoing litigation also adds a negative element.

Positives

• The company's net loss decreased significantly year-over-year.
• Research and development expenses decreased due to the completion of clinical studies.
• The company secured a substantial grant from the U.S. Department of Defense for long COVID research.
• The company has made progress in its clinical programs for AD, PD, and liver disease.
• The company has a novel liquid formulation of terlipressin for BIV201 that is stable at room temperature.

Negatives

• The Phase 3 AD trial was underpowered due to significant protocol deviations at some study sites.
• The company has not generated any revenue to date and has an accumulated deficit of approximately $334.2 million.
• The company's future operations are dependent on its ability to raise additional capital.
• The company is subject to a securities class action litigation.

Risks

• The company's reliance on third parties for clinical trials could lead to delays or failures.
• The development of biopharmaceuticals is highly uncertain and subject to numerous risks.
• The company may not be able to obtain regulatory approval for its product candidates.
• The company may not be able to commercialize its product candidates successfully.
• The company may not be able to raise sufficient capital to fund its operations.
• The company is subject to securities class action litigation.
• The company has limited manufacturing experience and relies on third parties.
• The company may not be able to protect its intellectual property rights.
• The company's stock price is volatile and may decline.
• The company may experience future dilution as a result of future equity offerings.

Future Outlook

The company anticipates commencing a Phase 2 clinical trial for long COVID by early 2025 and is finalizing protocol designs for a Phase 3 study of BIV201 for ascites. The company is also exploring options for continuing the AD trial or designing a new Phase 3 study.

Management Comments

• Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.
• Management continues to pursue the Companys strategic plans.

Industry Context

The company operates in the highly competitive biotechnology and biopharmaceutical industries, facing competition from other companies developing therapies for neurological disorders and liver disease. The company's focus on inflammation and insulin resistance in neurodegenerative diseases aligns with emerging scientific consensus.

Comparison to Industry Standards

• The company's approach to targeting inflammation and insulin resistance in neurodegenerative diseases is similar to other companies exploring these pathways, such as Denali Therapeutics and AC Immune.
• The company's Phase 3 AD trial results, while underpowered, are comparable to other companies' early-stage results in terms of observed cognitive slowing, such as Biogen's Aduhelm and Eisai's Leqembi.
• The company's Phase 2 PD trial results are similar to other companies' early-stage results in terms of improvements in motor and non-motor symptoms, such as Neurocrine Biosciences' Ingrezza and AbbVie's Duopa.
• The company's BIV201 program for ascites is unique in that it is a continuous infusion of terlipressin, which is different from other companies' approaches, such as Mallinckrodt's terlipressin for hepatorenal syndrome.

Legal Proceedings

• The company is subject to a securities class action lawsuit alleging material misrepresentations and/or omissions of material fact relating to the company's business, operations, compliance, and prospects, including information related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate probable AD.

Related Party Transactions

• The company entered into a securities purchase agreement with Acuitas Group Holdings, LLC, the company's largest stockholder, for the purchase of common stock and warrants.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings.
• Employees may be affected by the company's financial performance and potential restructuring.
• Patients may benefit from the company's development of new therapies.
• Creditors may be affected by the company's ability to repay its debts.

Next Steps

• Finalizing protocol designs for the Phase 3 study of BIV201 for ascites.
• Commencing a Phase 2 clinical trial for long COVID by early 2025.
• Exploring options for continuing the AD trial or designing a new Phase 3 study.
• Seeking additional financing to fund operations.

Key Dates

Keywords

BioVie, bezisterim, NE3107, BIV201, Alzheimer's disease, Parkinson's disease, long COVID, liver cirrhosis, ascites, clinical trials, biopharmaceutical, drug development, FDA, Orphan Drug, Fast Track, neurodegenerative, inflammation, insulin resistance